Therapeutic potential of interleukin-1 receptor antagonist in inflammatory bowel disease.
The therapeutic role of interleukin (IL)-1 receptor antagonist, a potent inhibitor of IL-1, was investigated using peripheral blood mononuclear cells from patients with ulcerative colitis and Crohn's disease. Administration of IL-1 receptor antagonist inhibited IL-1 beta-augmented IL-1 alpha and tumor necrosis factor-alpha production by mononuclear cells. Prednisolone caused a decrease in IL-1 receptor antagonist release, whereas sulfasalazine had no modulatory effect. Interestingly, IgG caused an increase in IL-1 receptor antagonist release. In conclusion, IL-1 receptor antagonist and related molecules may have therapeutic value.
Second Department of Medicine, Kurume University School of Medicine, Japan.
S
S
Shigematsu
D002478:Cells, Cultured; D004353:Drug Evaluation, Preclinical; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors*
D017472:Receptors, Interleukin-1